Earnings Releases·Nov 9, 2026, 6:35 AM ET

Abeona Therapeutics — Third Quarter 2026 Earnings Summary

Net ZEVASKYN revenue rose 18% sequentially to $13.5 million, driving a significant reduction in the net loss to $(4.8) million from $(20.2) million in the prior quarter, while total revenues reached $13.5 million compared to $0 in the same period last year.
The company acquired APT-1011 (renamed ABO-801), a Phase 3-ready EoE therapy, by issuing $20 million in common stock with potential future milestone payments up to $60 million, and secured commercial milestone and royalty rights from Ultragenyx's FDA approval of FAYUVI.
ZEVASKYN commercialization expanded with eight Qualified Treatment Centers now active, including new sites at Children's Hospital of Philadelphia and UT Medical Branch, while New Technology Add-On Payment (NTAP) status became effective October 1, 2026.
A $30 million private placement (PIPE) financing was completed post-quarter end to support pipeline development and commercialization, though cash and investments declined to $134.9 million during the quarter due to operating burn and asset reductions.